Low frequency mutation of the Ephrin receptor A3 gene in hepatocellular carcinoma

被引:19
|
作者
Bae, H. J. [1 ]
Song, J. H. [1 ]
Noh, J. H. [1 ]
Kim, J. K. [1 ]
Jung, K. H. [1 ]
Eun, J. W. [1 ]
Xie, H. J. [1 ]
Ryu, J. C. [2 ]
Ahn, Y. M. [3 ]
Kim, S. Y. [1 ]
Lee, S. H. [1 ]
Yoo, N. J. [1 ]
Lee, J. Y. [1 ]
Park, W. S. [1 ]
Nam, S. W. [1 ]
机构
[1] Catholic Univ Korea, Coll Med, Dept Pathol, Microdissect Genom Res Ctr, Seoul 137701, South Korea
[2] Korea Inst Sci & Technol, Cellular & Mol Toxicol Lab, Seoul 130650, South Korea
[3] Kyung Hee Univ, Dept Kidney Syst, Coll Oriental Med, Seoul, South Korea
关键词
Eph receptor; EphA3; hepatocellular carcinoma; mutation; SOMATIC MUTATIONS; CANCER; CELLS; EXPRESSION; GENOMICS; MELANOMA; SCREEN; FAMILY;
D O I
10.4149/neo_2009_04_331
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
EphA3 is a component of the Eph/ephrin tyrosine kinase system, which participates in vasculature development. This receptor/ligand system is associated with various signaling pathways related to cell growth and viability, cytoskeletal organization, cell migration, and anti-apoptosis. Accumulated evidence suggests that aberrant regulation of EphA3 and its genetic alterations are implicated in the development and progression of various cancers. However, despite a high incidence of EphA3 over-expression, no such investigation has been performed in hepatocellular carcinoma. Thus, we investigated genetic alterations of the EphA3 gene in 73 cases of hepatocellular carcinoma by single-strand conformational polymorphism and sequencing. One novel D219V missense mutation was found in the extracellular domain of EphA3, and two genetic alterations in the intracellular sterile-a-motif (SAM) domain of EphA3 appeared to be polymorphisms. Although the functional assessments of this mutant are incomplete, it is believed that this novel EphA3 mutation may contribute to the development of hepatocellular carcinoma.
引用
收藏
页码:331 / 334
页数:4
相关论文
共 50 条
  • [1] Overexpression of Ephrin A3 Receptor in Canine Prostatic Carcinoma
    Hood, G.
    Laufer-Amorim, R.
    Fonseca-Alves, C. E.
    Palmieri, C.
    JOURNAL OF COMPARATIVE PATHOLOGY, 2016, 154 (2-3) : 180 - 185
  • [2] Association of Ephrin receptor A3 gene polymorphism with susceptibility to chronic severe hepatitis B
    Yang, Hong
    He, Xing-Xing
    Song, Qi-Long
    Chen, Man
    Li, Jin
    Wang, Meng-Yi
    Yu, Jin-Ling
    Yao, Jin-Jian
    Liu, Li-Feng
    Lin, Ju-Sheng
    HEPATOLOGY RESEARCH, 2012, 42 (08) : 790 - 797
  • [3] Clinicopathological and prognostic significance of Ephrin A3 in bladder urothelial carcinoma
    Wang, Yi-Fan
    Hu, Yu-Ning
    Shen, Ze-Fan
    Zhao, Chang-Feng
    Liu, Kun
    Wang, Heng
    Zhang, Qi
    ONCOLOGY LETTERS, 2023, 26 (06)
  • [4] Low Frequency of PIK3CA Gene Mutations in Hepatocellular Carcinoma in Chinese Population
    Li, Xun
    Zhang, Quanbao
    He, Wenting
    Meng, Wenbo
    Yan, Jun
    Zhang, Lei
    Zhu, Xiaoliang
    Liu, Tao
    Li, Yumin
    Bai, Zhongtian
    PATHOLOGY & ONCOLOGY RESEARCH, 2012, 18 (01) : 57 - 60
  • [5] β-catenin accumulation and mutation of exon 3 of the β-catenin gene in hepatocellular carcinoma
    Kondo, Y
    Kanai, Y
    Sakamoto, M
    Genda, T
    Mizokami, M
    Ueda, R
    Hirohashi, S
    JAPANESE JOURNAL OF CANCER RESEARCH, 1999, 90 (12): : 1301 - 1309
  • [6] Utilization of the A3 adenosine receptor to treat hepatocellular carcinoma (HCC): From bench to bedside
    Fishman, P.
    Stemmer, S. M.
    Ochaion, A.
    Cohn, S.
    Patoka, R.
    Barer, F.
    Bar-Yehuda, S.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2009, 24 : S5 - S5
  • [7] bcl 10 gene mutation in hepatocellular carcinoma
    Cheng, JH
    Leng, XS
    Cai, SL
    Cao, ZX
    Cao, G
    Peng, JR
    Wang, SW
    Du, RY
    CHINESE MEDICAL JOURNAL, 2001, 114 (07) : 747 - 751
  • [8] Mutation of the DR5/TRAIL receptor 2 gene is infrequent in hepatocellular carcinoma
    Jeng, YM
    Hsu, HC
    CANCER LETTERS, 2002, 181 (02) : 205 - 208
  • [9] Gene mutation of transforming growth factor β1 type II receptor in hepatocellular carcinoma
    Furuta, K
    Misao, S
    Takahashi, K
    Tagaya, T
    Fukuzawa, Y
    Ishikawa, T
    Yoshioka, K
    Kakumu, S
    INTERNATIONAL JOURNAL OF CANCER, 1999, 81 (06) : 851 - 853
  • [10] The A3 adenosine receptor (A3AR) as a surrogate marker and therapeutic target in hepatocellular carcinoma (HCC).
    Fishman, P
    Bar Yehuda, S
    Stemmers, S
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9146S - 9146S